Metoprolol Ratiopharm (Metoprolol Tartrate)

Metoprolol selectively blocks β1‑adrenergic receptors in cardiac tissue, reducing the influence of adrenaline and noradrenaline. This leads to a slower heart rate, decreased contractile force, and lower cardiac output, which together help lower blood pressure and lessen the heart’s oxygen demand.

The appropriate dose of Metoprolol Ratiopharm is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and other factors such as age and kidney function. Patients should follow the specific dosing instructions provided by their healthcare professional.

Safety data for Metoprolol Ratiopharm in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metoprolol is a cardio‑selective beta‑blocker, offering advantages in patients with concomitant heart disease because it reduces heart rate and myocardial oxygen demand. Compared with non‑selective beta‑blockers, it has a lower risk of bronchospasm, but it may be less effective than some ACE inhibitors or calcium‑channel blockers for isolated hypertension.

Metoprolol Ratiopharm tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

Metoprolol Ratiopharm is taken orally, usually with or without food, as directed by a healthcare professional. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious risks include severe bradycardia, heart block, marked hypotension, and bronchospasm, especially in patients with underlying respiratory disease. Prompt medical attention is required if symptoms such as fainting, extreme fatigue, difficulty breathing, or chest pain occur.

Metoprolol Ratiopharm is contraindicated in individuals with known hypersensitivity to metoprolol or any component of the formulation, in patients with severe bradycardia, second‑ or third‑degree AV block without a pacemaker, and in those with uncompensated heart failure or severe peripheral arterial disease.